Strategic plans of ANVISA and COFEPRIS to advance health regulation

Home/Policies & Legislation | Posted 11/03/2024 post-comment0 Post your comment

ANVISA and COFEPRIS, Brazilian and Mexican health regulatory agencies respectively, unveil strategic plans for 2024-2027. ANVISA prioritizes World Health Organization (WHO) recognition, identification of medicinal products (IDMP) standards adoption, and biosimilar drug development. COFEPRIS focuses on regulatory certainty, digitalization, and aligning with global manufacturing standards.

11 AA010165

The Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), through a new strategic plan, has outlined its objectives for the next three years (2024-2027), aiming to gain recognition from the WHO while prioritizing initiatives like adopting IDMP standards and modernizing data platforms.

The formulation of ANVISA Strategic Plan for 2024‒2027 cycle began with the realisation of the situational diagnosis, adopting approaches and data collection tools. After that, a Strategic Map was drawn up. The map was made up of the organisational identity and seven strategic objectives, taking into account present and future challenges.

Based on the strategic objectives, established the strategic focuses and, in turn, defined the key results as parameters for measuring and evaluation of these objectives.  Finally, a portfolio of strategic projects was built from the perspective of agile management for results, in line with the guidelines established in the Strategic Map.

For ANVISA the specific goals outlined in the new plan involve supporting the process of bringing biological agents to the commercial market within two years after receiving marketing approval and enhancing the quantity of biosimilar medicines or groundbreaking drugs developed in Brazil by a 20% increment. By May 2023, Brazil had 52 follow-on biological medicines and approximately 30 biological products awaiting analysis or already being analysed by ANVISA [1].

Similarly, Mexico’s Federal Commission for the Protection Against Health Risks (COFEPRIS, Comisión Federal para la Protección contra Riesgos Sanitarios) has disclosed its agenda for 2024, focusing on enhancing regulatory certainty, promoting digitalization, and improving manufacturing capabilities in line with international standards.

COFEPRIS released a document on 30 January 2024 making also public its priorities and work agenda for 2024. They described efforts to promote regulatory certainty, improve confidence in its processes, and expand digitalization as a strategy to speed approvals.
COFEPRIS announced plans for the launch of its biosimilars unit and pharmaceutical development committee in 2024. These initiatives aim to boost Mexican manufacturing. The agency also pledged to improve rules for conducting clinical research to speed up service times.

Regarding medical devices, COFEPRIS aims to harmonize its good manufacturing practice (GMP) requirements with global standards, integrate into the Medical Device Single Audit Program, and remove trade barriers caused by labelling differences. Additionally, COFEPRIS released new detailed guides for registering devices and medicines in Mexico in December 2024. 

On 31 May 2021, COFEPRIS introduced a new decree which specified changes to the Health Supplies Regulation (Reglamento de Insumos para la Salud, RIS) [2]. 

Related articles
Public consultation for the modification of the biosimilars regulation in Brazil

COFEPRIS promotes regulatory cooperation in the Americas

Key facts of biosimilars approval regulation in Brazil

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: La FDA aprueba el biosimilar intercambiable de adalimumab Simlandi

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: La FDA aprueba el biosimilar intercambiable de adalimumab Simlandi

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. Cestari de Oliveira SH. Follow-on biologicals/biosimilars approved in Brazil: May 2023 update. Generics and Biosimilars Initiative Journal (GaBI Journal). 2023;12(2):67-72. doi:10.5639/gabij.2023.1202.012
2. GaBI Online - Generics and Biosimilars Initiative.  Mexico introduces new decree on health regulation []. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Mar 11]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Panama enacts new bill to guarantees the supply of medicines
53 MD002445
Home/Policies & Legislation Posted 29/02/2024
COFEPRIS promotes regulatory cooperation in the Americas
Latin America 1638px
Home/Policies & Legislation Posted 12/12/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010